Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is expected to be releasing its earnings data after the market closes on Thursday, February 27th. Analysts expect Cardiff Oncology to post earnings of ($0.26) per share and revenue of $0.09 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Cardiff Oncology Trading Down 7.2 %

Shares of CRDF opened at $4.23 on Wednesday. The stock’s 50 day moving average is $4.07 and its two-hundred day moving average is $3.20. The firm has a market cap of $216.30 million, a P/E ratio of -4.50 and a beta of 1.77. Cardiff Oncology has a 12 month low of $1.66 and a 12 month high of $6.42.

Analysts Set New Price Targets

Several research firms recently issued reports on CRDF. Piper Sandler boosted their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright lowered their price objective on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 8th.

Insider Transactions at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $2.60 per share, with a total value of $910,299.00. Following the purchase, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 7.60% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.